Inklusionskriterier:	Ja	Nej
1: Histologically proven classical Hodgkin lymphoma		
2: First diagnosis, no previous treatment except prephase as outlined below (5.4.1)		
3: Age: 60 years or older		
4: Advanced stages: Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease		
5: ECOG performance status ≤ 2 or ≤ 3 if due to HL		
6: CIRS-G score of ≤ 6 and ≤ 3 per organ system (except score 4 for eye, ear, nose and throat)		
7: Voluntary written informed consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.		
8: Female patient is either post-menopausal for at least one year before the screening visit or surgically sterile or if of childbearing potential, agree to practice two effective methods of contraception, at the same time, from the time of signing the informed consent through six months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.		
9: Male patients, even if surgically sterilized (i.e., status post vasectomy), agree to practice effective barrier contraception during the entire study period and through six months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.		
10: Negative HIV test		
11: Screening laboratory values must meet the following criteria: - Hemoglobin ≥8.0 g/dl, WBC ≥1500/µl; neutrophils ≥1500/µl; platelets ≥75,000/µl (unless due to HL) - Alkaline phosphatase <3 ULN, AST or ALT <3 ULN, serum total bilirubin <1.5 ULN (unless diagnosed with Gilbert's Syndrome)* - INR 2 and an aPTT 2 ULN unless due to anticoagulation		
12: Creatinine clearance > 40 ml/min as estimated by the Cockroft-Gault formula* *Refer to section 5.4.5.7 on dose reduction in case of renal impairment and liver impairment		
13: Life expectancy > 3 months		

Eksklusionskriterier:	Ja	Nej
1: Incomplete diagnosis of the disease stage		
2: Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)		
3: Prior chemotherapy or radiation for HL except prephase as outlined in the protocol		
4: Prior chemotherapy containing anthracyclines		
5: Concurrent disease which precludes protocol treatment, in particular the following conditions: - Chronic obstructive pulmonary disease (requiring ≥ 2 inpatient treatments due to exacerbation within 1 year) - History of myocardial infarction ≤ 6 months prior to first dose of study drug - Symptomatic ischemic heart disease, ongoing arrhythmias of Grade > 2, or any other cardiac condition (e.g. pericardial effusion restrictive cardiomyopathy) within six months prior to first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed. - Heart failure ≥ NYHA II and/or EF <50% (MUGA scan or echocardiography) - Uncontrolled hypertension despite appropriate medication - Uncontrolled active infection - Chronic active or persisting (positive PCR) hepatitis B and/or hepatitis C		
6: Ongoing long-term (i.e. >6 months) ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate)		
7: Peripheral neuropathy greater than CTC Grade 1		
8: Female patients who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on day 1 before first dose of study drug		
9: Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol		
10: Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of PML		

Eksklusionskriterier:	Ja	Nej
11: Symptomatic neurologic disease compromising normal activities of daily living or requiring medications		
12: Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within two weeks prior to first study drug dose		
13: Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least five half-lives of last dose of that prior treatment		
14: Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin		
15: Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection		
16: Diagnosed or treated for another malignancy within three years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection		
17: Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly		
18: Non-compliance		
19: General intolerance of any protocol medication		
20:Patients who have a relationship of dependence or employer-employee relationship to the sponsor or the investigator		
21: Committal to an institution on judicial or official order		
22: Participation in another interventional trial that could interact with this trial		

Dato: ___/___ 20__ Læge (underskrift): _____ Læge (init): ____